Home | Sitemap | Contact Us | Login   
Announcements

Quick Search Article: Category:

There are 27 records that matched your search criteria (sorted by : Date DESC order)
Date Title Category
13-Oct-2009 Caution Statement on “Severe Drug Interaction Between Colchicine and P-Glycoprotein or Strong CYP3A4 Inhibitors” required to be included in the product package insert for Colchicine
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
13-Oct-2009 Caution Statement on “Increased Risk for Opportunistic Infections such as Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy” required to be included in the product package insert for Immunosuppressant
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
15-Sep-2009 Advertisement on Products for nicotine replacement therapy with MAB Approval
Bil (37) dlm KKM-55/205/001/02 Jld 5 dated 15th Sept 2009
MAB Letter
14-Sep-2009 Caution Statement on “Potential for an Increase in Risk of Suicidal Thoughts or Behaviours” required to be included in the product package insert for Antiepileptik.
Bil (43) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel
Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters

Previous | 1 | 2

21 - 27 of 27 results